于雯华Yu, Jocelyn Ph.D.

律师

圣地亚哥 + 1.858.314.1186

于雯华博士的执业重点是协助生命科学领域的企业,以最大限度地保护知识产权并在国际商业战略和交易中利用知识产权。她所服务的客户群涵盖从生物技术初创企业直至大型国际药企的不同阶段和类型的企业。

Jocelyn 协助客户构建、扩展并管理全球专利池。她在设计、起草以及申请全球多国专利方面拥有着丰富的经验。她所涉足的技术领域主要包括免疫疗法(包括抗体、免疫细胞因子、下一代抗体技术平台)、基因疗法(包括基于mRNA、病毒或非病毒载体的疗法)、细胞疗法(包括CAR-T、干细胞、iPSC、CAR-NK疗法)、诊断和精准医学、基因编辑(CRISPR)、天然多肽技术平台、以及微生物工程技术。她还经常为辅助客户的知识产权、科研以及商业决策开展相应的尽职调查并提供法律意见,其中包括专利评估、知识产权地图检索、可专利性意见、专利有效性意见以及自由实施意见。

Jocelyn还协助生物技术和制药公司进行技术交易与合作(包括知识产权许可交易、资助研发以及联合研发合作),并着重于美国与亚洲之间的跨境交易。她经常协助客户谈判、审阅和起草各种涉及知识产权权益的商业协议书,并为支持交易开展法律、技术、知识产权完备性,以及药物监管合规方面相应的尽职调查。

Jocelyn拥有武汉大学药理学学士学位(2004年)、宾夕法尼亚州立大学遗传学博士学位(2010年)和美国西北大学法学博士学位(2016年)。在获得法学博士学位之前,她曾在位于美国加州的两家国际性律师事务所担任了总共四年的专利代理人工作。

经验

  • VST Bio establishes global patent portfolios related to anti-syndecan-2 antibodies for the treatment of diseases related to vascular permeabilityJones Day is representing VST Bio Corp. in connection with the establishment of a global patent portfolio related to antibodies that target syndecan-2 and uses thereof in the treatment of diseases related to vascular permeability and leakage, including ischemic stroke and myocardial infarction.
  • Incyte grants rights to CMS for ruxolitnib cream in China and Southeast AsiaJones Day represented Incyte Corporation in its Collaboration and License Agreement with CMS Aesthetics Limited for the development and commercialization of ruxolitinib cream, a novel cream formulation of Incyte’s selective JAK inhibitor ruxolitinib, for the treatment of autoimmune and inflammatory dermatologic diseases in Greater China and certain countries in Southeast Asia. 
  • DNARx develops global patent portfolios for HEDGES™ gene therapy platformJones Day represents DNARx, LLC in the development and prosecution of global patent portfolios related to HEDGES™ (High-level Extended Duration Gene Express System), DNARx's proprietary non-viral gene therapy together with gene-based, highly combinatorial anti-pandemic monoclonal antibody cDNA-encoded protein delivery platform technology for the treatment of various unmet medical needs.
  • Suzhou Abogen Biosciences establishes global patent portfolios for mRNA-based vaccines and nano-delivery platform technologiesJones Day represents Suzhou Abogen Biosciences Co., Ltd. in the establishment and prosecution of global patent portfolios related to mRNA-based vaccines for infectious diseases, such as COVID-19, as well as nano-delivery platform technologies.
  • AbbVie acquires Mitokinin, Inc.Jones Day advised AbbVie Inc. in its exclusive right to acquire Mitokinin, Inc., a biotechnology company developing PINK1-targeted therapeutics for the treatment of neurodegenerative diseases, following completion of IND enabling studies on Mitokinin's lead PINK1 compound.
  • Burning Rock establishes global patent portfolio for NGS-related diagnostics and precision oncologyJones Day represents Burning Rock in the development and prosecution of global patent portfolios related to next generation sequencing (NGS) technology for diagnostic and of precision oncology.
  • Junshi and Lilly to develop and commercialize antibodies for prevention and treatment of COVID-19 coronavirusJones Day represented Shanghai Junshi Biosciences Co., Ltd. in its strategic collaboration and license agreement with Eli Lilly and Company for the development, manufacturing, and commercialization of two antibodies for the prevention and treatment of the COVID-19 SARS-CoV-2 novel coronavirus.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • VersaPeutics collaborates with UCSD in developing pharmaceutical candidates for treatment of neurological and oncological diseasesJones Day represented VersaPeutics, Inc. in its strategic collaboration and license agreement with University of California San Diego ("UCSD") for the development of pre-clinical stage therapeutic candidates for the treatment of certain neurological and oncological diseases.
  • Sanofi and Denali Therapeutics collaborate to develop treatments for neurological and inflammatory diseasesJones Day represented Sanofi in its strategic collaboration and license agreement with Denali Therapeutics for the development, manufacturing, and commercialization of many pre-clinical and clinical candidates for treatment of certain neurological and systemic inflammatory diseases, including those known to target RIPK1, such as MS, Alzheimer's Disease and ALS, and rheumatoid arthritis.
  • Celgene acquires Juno Therapeutics for $9 billionOn behalf of Celgene Corporation, Jones Day conducted a large-scale intellectual property due diligence review and evaluation of matters related to its definitive merger agreement and acquisition of Juno Therapeutics for approximately $9 billion, including Juno’s technology related to CAR-T and TCR cellular immunotherapeutics for use in oncology and other indications.
  • Celgene develops global patent portfolio for agonistic anti-PD1 antibody therapeuticsJones Day represents Celgene Corporation in the establishment of a global patent portfolio related to agonistic anti-PD1 therapeutic antibodies.
    • October 27, 2022
      Practical Considerations in Continuation/Divisional Patent Application Practice
    • September 28, 2022
      Key topics for negotiation in Cross-the-Border Out-Licensing of Pharmaceutical Assets and Case Studies (Presentation in Mandarin)
    • January 25, 2022
      Key Topics For Negotiation in Life Science Licensing Transactions
    • November 7, 2018
      Licensing Fundamentals for Business Executives and Startups